(Q48956772)

17 February 2018

title

Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. (English)

1 reference

17 February 2018

0 references

Luca Prosperini

1

1 reference

17 February 2018

Costanza Giannì

2

1 reference

17 February 2018

Laura Leonardi

3

1 reference

17 February 2018

Laura De Giglio

4

1 reference

17 February 2018

Giovanna Borriello

5

1 reference

17 February 2018

Simonetta Galgani

6

1 reference

17 February 2018

Carlo Pozzilli

7

1 reference

17 February 2018

Claudio Gasperini

8

1 reference

17 February 2018

publication date

9 August 2011

1 reference

17 February 2018

Multiple Sclerosis Journal

published in

1 reference

17 February 2018

volume

18

1 reference

17 February 2018

page(s)

64-71

1 reference

17 February 2018

issue

1

1 reference

17 February 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Freedom from disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Basic methods for sensitivity analysis of biases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Switching multiple sclerosis patients with breakthrough disease to second-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

A method for evaluating treatment switching criteria in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458511417481

21 January 2018

Identifiers

DOI

10.1177/1352458511417481

1 reference

17 February 2018

PubMed ID

21828195

1 reference

17 February 2018